Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf Minimization and ACEi/ARB in Renal Transplant
NCT00933231Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2009
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplant rejection (4 arms), sponsored by Astellas Pharma. Primary endpoints: Interstitial Fibrosis and Tubular Atrophy at 24 months and Progression of Interstitial Fibrosis and Tubular Atrophy at 24 months. Started Aug 2009; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00933231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00933231.